Nangibotide
Septic Shock
About Inotrem
Inotrem is a clinical-stage biotech pioneering therapies that modulate the TREM-1 pathway, a key amplifier of inflammatory responses. The company's most advanced asset, nangibotide, is a TREM-1 inhibitor being evaluated in Phase 2b/3 trials for septic shock, a condition with high mortality and no approved targeted therapy. With a platform that could apply to multiple inflammatory conditions, Inotrem is positioning itself in the high-need critical care and immunology markets. The company has secured significant venture funding and strategic partnerships to advance its pipeline.
View full company profileAbout Inotrem
Inotrem is a clinical-stage biotech pioneering therapies that modulate the TREM-1 pathway, a key amplifier of inflammatory responses. The company's most advanced asset, nangibotide, is a TREM-1 inhibitor being evaluated in Phase 2b/3 trials for septic shock, a condition with high mortality and no approved targeted therapy. With a platform that could apply to multiple inflammatory conditions, Inotrem is positioning itself in the high-need critical care and immunology markets. The company has secured significant venture funding and strategic partnerships to advance its pipeline.
View full company profileTherapeutic Areas
Other Septic Shock Drugs
| Drug | Company | Phase |
|---|---|---|
| Centhaquine | Pharmazz | Phase 2 |
| Enibarcimab (Adrecizumab) | Adrenomed | Phase 2 |